Therefore, an increase in adiponectin secretion and decrease in resistin secretion are considered to have a synergistically beneficial effect on inhibiting the progress of MS associated with obesity and diabetes. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.